CC BYAureliane C. S. PierretMadeleine BentonKhalida IsmailPiya Sen Gupta2025-06-142025-06-142024-11-091432-523310.1007/s00592-024-02392-0https://ror.circle-u.eu/handle/123456789/463605<jats:title>Abstract</jats:title><jats:sec> <jats:title>Objective</jats:title> <jats:p>Obesity and type 2 diabetes (T2D) are associated with increased rates of mental disorders, particularly depression, anxiety and binge-eating disorder. GLP-1 receptor agonists are a novel class of pharmacological agents for obesity and T2D. We aimed to describe participants’ experiences of GLP-1 receptor agonists on their mental health.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>Qualitative, individual, semi-structured interviews were conducted in nine participants who were prescribed GLP-1 receptor agonists for the treatment of obesity and/or T2D. Mental health status was measured at time of GLP-1 receptor agonist initiation and assessed again at 12–16 weeks when the semi-structured interview took place. Data were analysed using reflexive thematic analysis.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>Three main themes were generated from the analysis: (1) acceptance of negative side effects for long term physical health benefits; (2) reflections on the diverse impact on mental health; (3) reduced appetite and increased control of eating behaviours.</jats:p> </jats:sec><jats:sec> <jats:title>Discussion</jats:title> <jats:p>Overall, participants with obesity and/or T2D described a positive impact of GLP-1 receptor agonists on their mental health, especially perception of improved control of eating behaviours. This suggests GLP-1 receptor agonists should be further studied for their potential effectiveness for treatment of binge-eating disorder.</jats:p> </jats:sec>OPEN616610publication03 medical and health sciences0302 clinical medicinedoi_dedup___